Novartis subsidiary Alcon has obtained CE mark approval for its AcrySof IQ PanOptix trifocal intraocular lens (IOL) to be used for patients undergoing cataract surgery.
The new trifocal presbyopia-correcting intraocular lens were designed for patients undergoing cataract surgery who elect to address their near, intermediate and distance vision needs with a single lens.
Alcon surgical franchise research and development head Franck Leveiller said: "The AcrySof IQ PanOptix trifocal IOL is a significant innovation which further augments Alcon’s presbyopia correcting portfolio, leveraging Alcon’s market-leading AcrySof IQ IOL platform.
"It is designed to provide exceptional functional vision from near to intermediate, in addition to providing excellent distance vision." Presbyopia is an eye condition, which occurs as part of natural aging. Its first signs include eyestrain, difficulty seeing up close in dim light and problems focusing on small objects or fine point.
The AcrySof IQ PanOptix trifocal IOL is suggested for adult patients with and without presbyopia undergoing cataract surgery who desire near, intermediate and distance vision with increased spectacle independence.